Current Report Filing (8-k)
May 20 2022 - 5:30PM
Edgar (US Regulatory)
0001213660
false
116000
0001213660
2022-05-20
2022-05-20
0001213660
dei:FormerAddressMember
2022-05-20
2022-05-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
May 20, 2022
Date of Report
(Date of earliest event reported)
BIMI International Medical Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-50155 |
|
02-0563302 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.)
|
9th Floor, Building 2, Chongqing Corporation Avenue,
Yuzhong District, Chongqing, P. R. China
|
(Address of principal executive offices and zip code)
|
(86) 23-6310 7239 |
(Registrant’s telephone number, including area
code)
|
Not Applicable |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common stock, $0.001 par value |
|
BIMI |
|
The NASDAQ Capital Market |
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On May 20, 2022, the Registrant reported its results
of operations for the quarterly period ended March 31, 2022. A copy of the press release issued by the Registrant in this connection is
furnished herewith as Exhibit 99.1.
The information in this Item in this Current Report
on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation
language in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 20, 2022 |
BIMI International Medical Inc. |
|
(Registrant) |
|
|
|
|
By: |
/s/ Tiewei Song |
|
|
Tiewei Song |
|
|
Chief Executive Officer |
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Sep 2023 to Sep 2024